Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anatomic Stage IV Breast Cancer AJCC v8: early-phase trial registry
42 of 60 indexed Anatomic Stage IV Breast Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #235 of 28,707 conditions by registered trial count.
60 US clinical trials · 42 currently recruiting · #235 of 28,707 conditions by registered trial count
Anatomic Stage IV Breast Cancer AJCC v8: 60 US clinical trials tracked, 42 recruiting.
Anatomic Stage IV Breast Cancer AJCC v8 is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 16 of these trials.
Enrollment posture brief
Registry condition anatomic-stage-iv-breast-cancer-ajcc-v8
OPEN 42 | RECR 70% | LATE 4 | EARLY 47 | RANK #235 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Anatomic Stage IV Breast Cancer AJCC v8 lists 42 open slots (70% of 60 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anatomic Stage IV Breast Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anatomic Stage IV Breast Cancer AJCC v8 is recruiting above its size-band peers.
42 of 60 indexed trials (70%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anatomic Stage IV Breast Cancer AJCC v8 research.
National Cancer Institute (NCI) accounts for 16 of 60 trials (26.7%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Anatomic Stage IV Breast Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 60 trials that report a genuine target (sentinel values excluded). 47 of those (78.3%) plan for fewer than 100 participants.
-
Anatomic Stage IV Breast Cancer AJCC v8 research is mostly interventional.
56 interventional and 4 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
60 total, page 2 of 2
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Mridula George, MD
NCT04445844
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT03939897
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
NCT04345913
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03218826
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT04673448
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
NCT03179904
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
NCT05081492
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
NCT03941730
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
NCT03207529
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 25 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Anatomic Stage IV Breast Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anatomic Stage IV Breast Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anatomic Stage IV Breast Cancer AJCC v8 page
60 registered trials, 42 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 42 Anatomic Stage IV Breast Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Anatomic Stage IV Breast Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anatomic Stage IV Breast Cancer AJCC v8 condition card totals 60 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.